<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">BUPROPION HYDROCHLORIDE</span><br/>(byoo-pro'pi-on)<br/><span class="topboxtradename">Wellbutrin, </span><span class="topboxtradename"> Wellbutrin SR, </span><span class="topboxtradename">Wellbutrin XL, </span><span class="topboxtradename">Zyban<br/></span><b>Classifications:</b> <span class="classification">central nervous system (cns) agent</span>; <span class="classification">antidepressant</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>75 mg, 100 mg tablets; 100 mg, 150 mg, 200 mg sustained-release tablets; 150 mg, 300 mg extended-release tablets</p>
<h1><a name="action">Actions</a></h1>
<p>The neurochemical mechanism of bupropion is unknown. It does not inhibit monoamine oxidase. Compared to tricyclic antidepressants
         (TCA), it is a weak blocker of neural uptake of serotonin and norepinephrine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Its antidepressive effect is related to CNS stimulant effects.</p>
<h1><a name="uses">Uses</a></h1>
<p>Indicated for mental depression; since it has been associated with increased risk of seizures, it is not the agent of first
         choice; adjunct for smoking cessation.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Cyclic mood disorders, schizoaffective disorders.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to bupropion; history of seizure disorder; current or prior diagnosis of bulimia or anorexia nervosa; concurrent
         administration of an MAO inhibitor; head trauma; CNS tumor; recent MI; abrupt discontinuation, anorexia nervosa, bulimia nervosa,
         children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Renal or hepatic function impairment; drug abuse or dependence; pregnancy (category B); cardiac disease, MI, hepatic disease,
         biliary cirrhosis; hypertension, bipolar disorder, mania, psychosis, diabetes mellitus, older adults, ethanol intoxication,
         suicidal ideation, tics, Tourette's syndrome.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Depression</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 75100 mg t.i.d., start with 75 mg t.i.d., or 100 mg SR b.i.d., or 150 mg XL q.d., and  increase dose q3d to 300 mg/d; doses &gt;450 mg/d are associated with an increased risk of adverse reactions including seizures<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> 50100 mg/d, may increase by 50100 mg q34d (max: 150 mg/dose)<br/><br/><span class="indicationtitle">Smoking Cessation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 150 mg once daily <small>x</small> 3 d, then increase to 150 mg b.i.d. (max: 300 mg/d) for 712 wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meals to decrease incidence of nausea and vomiting.</li>
<li>Ensure that sustained-release tablets are not chewed or crushed. They must be swallowed whole.</li>
<li>
            				Note: Increases in dosage should not exceed 100 mg/d over a 3-d period. Greater increments increase the seizure potential.
            			
         </li>
<li>Store away from heat, direct light, and moisture.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Weight loss, weight gain. <span class="typehead">CNS:</span>
<span class="speceff-life">Seizures</span>. The risk of seizure appears to be strongly associated with dose (especially &gt;450 mg/d) and may be increased by predisposing
      factors (e.g., head trauma, CNS tumor) or a history of prior seizure; <span class="speceff-common">agitation, insomnia, dry mouth, blurred vision, headache, dizziness, tremor.</span>
<span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, constipation.</span>
<span class="typehead">CV:</span> Tachycardia. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase metabolism of <b>carbamazepine,</b>
<b>cimetidine,</b>
<b>phenytoin,</b>
<b>phenobarbital,</b> decreasing their effect; may increase incidence of adverse effects of <b>levodopa,</b>
<span class="classification">mao inhibitors</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Onset:</span> 34 wk. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Metabolism:</span> Metabolized in liver (including first pass metabolism) to active metabolites. <span class="typehead">Elimination:</span> 80% excreted in urine as inactive metabolites <span class="typehead">Half-Life:</span> 824 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness. The full antidepressant effect of drug may not be realized for 4 or more weeks.</li>
<li>Close observation for worsening of depression or suicidal tendencies.</li>
<li>Use extreme caution when administering drug to patient with history of seizures, cranial trauma, or other factors predisposing
            to seizures; during sudden and large increments in dose, seizure potential is increased.
         </li>
<li>Report significant restlessness, agitation, anxiety, and insomnia. Symptoms may require treatment or discontinuation of drug.</li>
<li>Monitor for and report delusions, hallucinations, psychotic episodes, confusion, and paranoia.</li>
<li>Lab tests: Monitor hepatic and renal function tests while patient is taking this drug.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug at the same times each day.</li>
<li>Monitor your weight at least weekly. Report significant changes in weight (+/5 lb) to physician.</li>
<li>Minimize or avoid alcohol because it increases the risk of seizures.</li>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known because judgment or motor and cognitive
            skills may be impaired.
         </li>
<li>Do not abruptly discontinue drug. Gradual dosage reduction may be necessary to prevent adverse effects.</li>
<li>Do not take any OTC drugs without consulting physician.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>